Brand Name :
pletal
Synonyms :
cilostazol
Class :
Antiplatelet agent
Dosage Forms & Strengths
Tablet
50mg
100mg
Indicated for Intermittent claudication:
100
mg
Orally
twice a day at least 30 minutes before meals or 2 hours after meals
Tablet
Safety and efficacy not established
Refer adult dosing
may enhance the concentration of serum when combined with cilostazol
may enhance the concentration of serum when combined with cilostazol
may enhance the concentration of serum when combined with cilostazol
may enhance the concentration of serum when combined with cilostazol
may enhance the concentration of serum when combined with cilostazol
cilostazol: they may enhance the serum concentration of CYP3A Inhibitors
cilostazol: they may enhance the serum concentration of CYP3A Inhibitors
cilostazol: they may enhance the serum concentration of CYP3A Inhibitors
cilostazol: they may enhance the serum concentration of CYP3A Inhibitors
cilostazol: they may enhance the serum concentration of CYP3A Inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may increase the anticoagulant effect of antiplatelet agents
may increase the serum concnetration when combined
may enhance the serum concentration of CYP3A4 Inhibitors
morphine (Systemic): they may decrease the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors)
omeprazole: they may enhance serum concentrations of cilostazol
may enhance serum concentrations of CYP2C19 Inhibitors
caplacizumab: they may increase the toxic effect of Antiplatelet agents
antiplatelet Properties may enhance the antiplatelet effect of abrocitinib
may enhances the effects of the other by pharmacodynamic synergism
antiplatelet agents increase the antiplatelet effect of abrocitinib
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
it May enhance the antiplatelet effect of Agents with antiplatelet Properties
antiplatelet agents may enhance the anticoagulant effect of thrombolytic Agents
choline magnesium trisalicylate
may enhance the adverse/toxic effect of salicylates
choline magnesium trisalicylate
may increase the risk of adverse effect of salicylates
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may enhance the risk of adverse effect of thrombolytic agents
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may increase the antiplatelet effect of other antiplatelet agents
may increase the antiplatelet effect of other antiplatelet agents
choline magnesium trisalicylate
may have an increasingly adverse effect when combined with salicylates
It may enhance the risk of bleeding by affecting coagulation when combined with omega-3 carboxylic acids
It may diminish the effect when combined with griseofulvin by CYP3A4 metabolism
it may diminish the metabolism when combined with azelastine
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
when bromazepam and cilostazol are used together, there is a potential reduction in the bromazepam's metabolism
the effect of cilostazol is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
it may increase the antiplatelet effect of properties of antiplatelet drugs
antiplatelet agents may enhance the adverse/toxic effect of ibritumomab tiuxetan
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
it may enhance the antiplatelet effect of Agents with antiplatelet Properties
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
may increase the antiplatelet effect of agents with antiplatelet properties
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the effect of other agents with antiplatelet drugs
may increase the antiplatelet effect of prostacyclin analogs
may enhance the effect of antiplatelet properties
may increase the anti-coagulant action of anti-coagulants
may increase the antiplatelet effect of antiplatelet agents
may increase the antiplatelet effect of other antiplatelet agents
may increase the antiplatelet effect of other antiplatelet agents
may have an increasingly adverse effect when combined with Apixaban
may have an increasingly adverse effect when combined with Cephalothin
May have an increased anticoagulant effect when combined with Antiplatelet agents
may have an increasingly adverse effect when combined with Deoxycholic Acid
may have an increasingly adverse effect when combined with Edoxaban
may increase the toxic effect of salicylates
may increase the antiplatelet effect of nonsteroidal anti-inflammatory agents
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased antiplatelet effect when combined with antiplatelet agents
may have an increased adverse effect when combined with ibritumomab tiuxetan
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
other antiplatelet agents increase the effect of anticoagulating agents
it increases the effect of antiplatelet agents
antiplatelet agents increase the effect of thrombolytic agents
it increases the effect of antiplatelet agents
antiplatelet agents increase the toxicity of obinutuzumab
they increase the efficacy of antiplatelet agents
it increases the efficacy of antiplatelet agents
it increases the efficacy of antiplatelet agents
it increases the toxicity of antiplatelet agents
may increase the adverse effect of pentosan polysulfate sodium
may increase the antiplatelet effect
may enhance the effects by pharmacodynamic synergism when combined with cilostazol
it increases the effect of antiplatelet agents
other antiplatelet agents increase the anticoagulative effect of rivaroxaban
lipid emulsion (plant oil-based)
lipid emulsion: they may increase the toxic effect of antiplatelet agents